NCT07349303
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07349303
Title Neoadjuvant Pembrolizumab in Patients With Stage IIb/c Melanoma, a Phase II Double-blind Placebo-controlled Randomized Trial (NEOPRIME)
Acronym NEOPRIME
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Vastra Gotaland Region
Indications
Therapies
Age Groups: adult | senior
Covered Countries SWE


No variant requirements are available.